NA
CPRX

Navellier & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Navellier & Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,616
Closed -$312K – 337
2026
Q1 		$312K Buy
12,616
+872
+7% +$20.8K 0.03% 278
2025
Q4 		$274K Sell
11,744
-1,602
-12% -$35.7K 0.03% 284
2025
Q3 		$263K Buy
13,346
+822
+7% +$16.9K 0.03% 324
2025
Q2 		$272K Hold
12,524
– – 0.03% 273
2025
Q1 		$304K Sell
12,524
-1,639
-12% -$36.9K 0.04% 254
2024
Q4 		$296K Buy
14,163
+1,869
+15% +$40.2K 0.04% 277
2024
Q3 		$244K Sell
12,294
-1,698
-12% -$31.5K 0.03% 294
2024
Q2 		$217K Buy
13,992
+164
+1% +$2.55K 0.03% 320
2024
Q1 		$220K Sell
13,828
-140,449
-91% -$2.12M 0.03% 317
2023
Q4 		$2.59M Buy
154,277
+17,663
+13% +$241K 0.39% 80
2023
Q3 		$1.6M Buy
136,614
+11,170
+9% +$149K 0.27% 97
2023
Q2 		$1.69M Buy
125,444
+718
+0.6% +$10.3K 0.33% 91
2023
Q1 		$2.07M Buy
124,726
+15,240
+14% +$251K 0.44% 83
2022
Q4 		$2.04M Buy
109,486
+4,448
+4% +$68.5K 0.41% 78
2022
Q3 		$1.35M Buy
+105,038
New +$1.24M 0.3% 91

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Navellier & Associates's CPRX Position: Q2 2026 in Review

Navellier & Associates sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 12,616 shares — an estimated $312K sold.

Navellier & Associates first reported a position in CPRX in Q3 2022 and held it in 15 quarters. The position peaked at $2.59M in Q4 2023. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Navellier & Associates reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Navellier & Associates sold 12,616 Catalyst Pharmaceutical shares in Q2 2026, an estimated $312K.
  • Navellier & Associates first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 15 quarters.
  • Navellier & Associates's Catalyst Pharmaceutical position peaked at $2.59M in Q4 2023.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.